Integrated Viral Hepatitis Surveillance, Testing, Treatment, and Prevention Programs for Health Departments (IVH-STTP)
Forecasted Federal grant Posted
- Opportunity number
- CDC-RFA-PS-27-0009
- Agency
-
Centers for Disease Control and Prevention
Department of Health and Human Services
- Applications expected due
- Award size
- Not on record
Opportunity facts
- Expected posting
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- State Governments
- Other
- City/Township Governments
- Special District Governments
- County Governments
- Points of contact
-
- Clarisse Tsang mix4@cdc.gov (404) 718-5360
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention is forecasting a cooperative agreement opportunity to support integrated viral hepatitis surveillance, testing, treatment, and prevention programs in states, territories, and large cities, with application submission expected in the coming months as part of the Viral Hepatitis Prevention and Control program (CFDA 93.270).
Eligible applicants include the 51 state health departments or their bona fide agents, local health agencies or their bona fide agents, and all U.S. territories. When a city lacks its own public health department, the covering county may apply. Bona fide agents must submit documentation demonstrating their arrangement with the eligible applicant.
The NOFO comprises four components: two required (Component 1: Outbreak Response and Surveillance; Component 2: Planning, Partnerships, and Promotion) and two optional (Component 3: Testing, Treatment, and Prevention; Component 4: Perinatal Hepatitis C Program). Recipients must conduct surveillance for hepatitis A, acute and chronic hepatitis B, and acute, chronic, and perinatal hepatitis C; develop and utilize disease registries; conduct data matching; and generate data summaries to monitor progress and inform case investigations. Prevention activities include supporting viral hepatitis elimination planning, expanding hepatitis B and C testing and treatment integration in high-impact settings, and developing perinatal hepatitis C programs. Expected outcomes include improved surveillance and reporting, strengthened strategic planning and partner collaboration, and expanded access to prevention, diagnosis, and treatment.
Cooperative agreements support a 12-month initial budget period with up to five years of total performance subject to availability of funds and satisfactory recipient progress. Funds support personnel, travel, supplies, and services for prevention program establishment and maintenance. Recipients may not use funds for clinical care or, generally, for furniture and equipment purchases unless identified and approved in the budget. Recipients must perform a substantial programmatic role and not serve merely as funding conduits.
Forecast synopsis
This NOFO supports integrated viral hepatitis surveillance and prevention programs in states, territories, and large cities in the United States. Key strategies include viral hepatitis outbreak response and surveillance for hepatitis A, acute and chronic hepatitis B, and acute, chronic, and perinatal hepatitis C. Surveillance activities include developing and utilizing disease registries, conducting data matching, generating data summaries, utilizing data to monitor program progress and inform program activities and to enhance case investigations for data-to-care opportunities, and strengthening health department infrastructure to expand surveillance capacity. Prevention activities include supporting viral hepatitis elimination planning, partnerships, and coordination in high-impact and healthcare settings, increasing hepatitis B and hepatitis C testing, treatment, and service integration in high-impact settings, and developing perinatal hepatitis C programs. Expected outcomes include improved surveillance and reporting of viral hepatitis, improved strategic planning and partner collaboration in viral hepatitis elimination, and expanded access to viral hepatitis prevention, diagnosis, and treatment in high-impact settings.
This multi-component NOFO includes two required components and two optional components:
- Component 1: Outbreak Response and Surveillance (Required)
- Component 2: Planning, Partnerships, and Promotion (Required)
- Component 3: Testing, Treatment, and Prevention (Optional)
- Component 4: Perinatal Hepatitis C Program (Optional)
This NOFO is alignment with CDC priorities.
Eligibility
Eligible applicants include: The 51 state health departments or their bona fide agents, including the District of Columbia. Local health agencies or their bona fide agents. If the city does not have a public health department, then the county covering the jurisdiction may apply (i.e., Los Angeles, CA covered by Los Angeles County and Phoenix, AZ covered by Maricopa County). All U.S. territories Bona fide agents must submit documentation that demonstrates their arrangement with the eligible applicant.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity